iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://doi.org/10.1038/gt.2012.101
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates | Gene Therapy
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates

Gene Therapy volume 20, pages 450–459 (2013)Cite this article

Subjects

A Corrigendum to this article was published on 04 April 2013

This article has been updated

Abstract

Injection of adeno-associated virus (AAV) into the cerebrospinal fluid (CSF) offers a means to achieve widespread transgene delivery to the central nervous system, where the doses can be readily translated from small to large animals. In contrast to studies with other serotypes (AAV2, AAV4 and AAV5) in rodents, we report that a naturally occurring capsid (AAV9) and rationally engineered capsid (AAV2.5) are able to achieve broad transduction throughout the brain and spinal cord parenchyma following a single injection into the CSF (via cisterna magna or lumbar cistern) in non-human primates (NHP). Using either vector at a dose of ∼2 × 1012 vector genome (vg) per 3–6 kg animal, approximately 2% of the entire brain and spinal cord was transduced, covering all regions of the central nervous system (CNS). AAV9 in particular displayed efficient transduction of spinal cord motor neurons. The peripheral organ biodistribution was highly reduced compared with intravascular delivery, and the presence of circulating anti-AAV-neutralizing antibodies up to a 1:128 titer had no inhibitory effect on CNS gene transfer. Intra-CSF delivery effectively translates from rodents to NHPs, which provides encouragement for the use of this approach in humans to treat motor neuron and lysosomal storage diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Change history

  • 04 April 2013

    This article has been corrected since online publication and a corrigendum is also printed in this issue.

References

  1. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187–1196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59–65.

    Article  CAS  PubMed  Google Scholar 

  3. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ . Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058–1069.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood–brain barrier (BBB). Mol Ther 2010; 18: 570–578.

    Article  CAS  PubMed  Google Scholar 

  5. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012; 23: 382–389.

    Article  CAS  PubMed  Google Scholar 

  6. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97: 3428–3432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liu G, Martins IH, Chiorini JA, Davidson BL . Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Therapy 2005; 12: 1503–1508.

    Article  CAS  PubMed  Google Scholar 

  8. Ghodsi A, Stein C, Derksen T, Martins I, Anderson RD, Davidson BL . Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol 1999; 160: 109–116.

    Article  CAS  PubMed  Google Scholar 

  9. Storek B, Harder NM, Banck MS, Wang C, McCarty DM, Janssen WG et al. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain 2006; 2: 4.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I . Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 2009; 5: 52.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vulchanova L, Schuster DJ, Belur LR, Riedl MS, Podetz-Pedersen KM, Kitto KF et al. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol Pain 2010; 6: 31.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kao JH, Chen SL, Ma HI, Law PY, Tao PL, Loh HH . Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm. J Pharmacol Exp Ther 2010; 334: 739–745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Snyder BR, Gray SJ, Quach ET, Huang JW, Leung CH, Samulski RJ et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 2011; 22: 1129–1135.

    Article  CAS  PubMed  Google Scholar 

  14. Storek B, Reinhardt M, Wang C, Janssen WG, Harder NM, Banck MS et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci USA 2008; 105: 1055–1060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Federici T, Taub JS, Baum GR, Gray SJ, Grieger JC, Matthews KA et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Therapy 2011; 19: 852–859.

    Article  PubMed  Google Scholar 

  16. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 2011; 22: 1143–1153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20: 443–455.

    Article  CAS  PubMed  Google Scholar 

  18. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704–712.

    Article  CAS  PubMed  Google Scholar 

  19. Swindle MM . Swine in the Laboratory: Surgery, Anesthesia, Imaging, and Experimental Techniques 2nd ed CRC Press Boca Raton, FL, 2007: 471.

    Book  Google Scholar 

  20. Morgan CJ, Pyne-Geithman GJ, Jauch EC, Shukla R, Wagner KR, Clark JF et al. Bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs. J Neurosurg 2004; 101: 1026–1029.

    Article  CAS  PubMed  Google Scholar 

  21. Pardridge WM . Transnasal and Intraventricular Delivery of Drugs. Peptide Drug Delivery to the Brain. Raven Press New York, 1991.

    Google Scholar 

  22. Pardridge WM . Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011; 8: 7.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Snyder BR, Gray SJ, Quach ET, Huang JW, Leung CH, Samulski RJ et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 2011; 22: 1129–1135.

    Article  CAS  PubMed  Google Scholar 

  24. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ . Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Therapy 2003; 10: 2112–2118.

    Article  CAS  PubMed  Google Scholar 

  25. McCarty DM, Monahan PE, Samulski RJ . Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 2001; 8: 1248–1254.

    Article  CAS  PubMed  Google Scholar 

  26. Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224–2232.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Grieger JC, Choi VW, Samulski RJ . Production and characterization of adeno-associated viral vectors. Nat Protoc 2006; 1: 1412–1428.

    Article  CAS  PubMed  Google Scholar 

  28. Paxinos G, Watson C . The Rat Brain in Stereotaxic Coordinates 6th edn Academic Press/Elsevier Amsterdam; Boston, 2007.

    Google Scholar 

  29. Hylden JL, Wilcox GL . Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980; 67: 313–316.

    Article  CAS  PubMed  Google Scholar 

  30. Sowa NA, Street SE, Vihko P, Zylka MJ . Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci 2010; 30: 10282–10293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by generous grants from Hannah’s Hope Fund (to SJG), Award Number UL1RR025747 from the National Center for Research Resources (to SJG), the Senator Paul D Wellstone Muscular Dystrophy Cooperative Research Center Grant U54-AR056953 (to RJS), NIH Research Grant 5R01AI072176-05 (to RJS) and NIH Research Grant NS35633 (to TJM), as well as a kind gift from the Jasper Against Batten Foundation at Partnership for Cures (for support of SJG’s research). We are extremely thankful to MPI Research for the quality and timeliness of the work and for help with study design; in particular, we would like to acknowledge the roles of Mark Johnson, Missy Peet and David Serota. We thank the UNC Vector Core, in particular Josh Grieger, for technical assistance with vector production. We also thank Lavanya Bachaboina, Huijing Sun and Erica Jones for help with tissue sectioning and IHC, Brendan Fitzpatrick and Jennifer Coleman in Mark Zylka’s laboratory (UNC) for help with intrathecal mouse injections and Swati Yadav and Hung-Jui ‘Sophia’ Shih for running qPCR reactions. We would also like to acknowledge Jim Wilson’s group at the University of Pennsylvania for the discovery of AAV9, and thank Xiao Xiao at UNC and the UNC Vector Core for providing the AAV9 helper plasmid.

Author information

Authors and Affiliations

  1. Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    S J Gray, S Nagabhushan Kalburgi, T J McCown & R Jude Samulski

Authors
  1. S J Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Nagabhushan Kalburgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T J McCown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Jude Samulski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S J Gray.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gray, S., Nagabhushan Kalburgi, S., McCown, T. et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20, 450–459 (2013). https://doi.org/10.1038/gt.2012.101

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2012.101

Keywords

This article is cited by

Search

Advanced search

Quick links